Researchers conducted a retrospective cohort study at three medical centers. They examined patients with monomicrobial Enterobacteriaceae bacteremia treated with in vitro active therapy for six to 16 days from 2008 through 2014. The patients were divided into a short-course antibiotic therapy group and prolonged-course group.
Researchers found the median duration of therapy in the short-course group and prolonged-course group was eight days and 15 days, respectively. There was no difference in mortality between the treatment groups.
The study also shows the odds of recurrent bloodstream infections and Clostridium difficile infections were also similar between the two groups. However, there was a “trend toward a protective effect of short-course antibiotic therapy on the emergence of [multidrug-resistant gram-negative] bacteria,” the study authors wrote.
More articles on healthcare quality:
Suspected norovirus outbreak sickens 100 at college in Michigan
Childhood vaccination rates increase 12% in 6 years
CDC wants to bring clinical guidelines into the ‘digital age’: 3 things to know
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
